0.5 %Twenty-three (0.5%) of the women living with HIV who were screened had suspected cervical cancer.
Nigeriacancer du col de l'utérusobserved March to August 2023published 2026BMC health services researchPubMeddocument of 5 observations
Gold tier: mechanically validated evidence, with its primary source.
298 evidence items · page 6 / 12
0.5 %Twenty-three (0.5%) of the women living with HIV who were screened had suspected cervical cancer.
Nigeriacancer du col de l'utérusobserved March to August 2023published 2026BMC health services researchPubMeddocument of 5 observations
76.3 %Majority (76.3%) considered screening important in cervical cancer prevention.
Nigeriacancer du col de l'utéruspublished 2020The Pan African medical journalPubMeddocument of 7 observations
Cervical cancer is the second leading cause of cancer death among women globally.
Nigeriacancer du col de l'utéruspublished 2024The Pan African medical journalPubMeddocument of 8 observations
93.6 %The majority of the female secondary school teachers in Enugu metropolis (93.6%) accepted the HPV vaccine and would recommend it for their children and students.
Nigeriacancer du col de l'utérusobserved 2017published 2021The Pan African medical journalPubMeddocument of 7 observations
12,000 casesCervical cancer is highly prevalent in Nigeria, with over 12,000 cases and 8000 deaths annually.
Nigeriacancer du col de l'utéruspublished 2025International journal of STD & AIDSPubMeddocument of 13 observations
6.8 %The overall knowledge of cervical cancer among the respondents was 6.8%.
Nigeriacancer du col de l'utérusobserved 2017published 2022The Pan African medical journalPubMeddocument of 7 observations
94.8 %Willingness to undergo cervical cancer screening was 94.8% among women aged 25 to 65 years in Makurdi, North-Central Nigeria.
Nigeriacancer du col de l'utéruspublished 2025Asian Pacific journal of cancer prevention : APJCPPubMeddocument of 6 observations
96.3 %Among 991 women of reproductive age living with HIV in North Central Nigeria, 96.3% had never been vaccinated against cervical cancer.
Nigeriacancer du col de l'utéruspublished 2025The Pan African medical journalPubMeddocument of 4 observations
80 %Over 80% of new cervical cancer cases occur in women living in low- and middle-income countries.
Nigeriacancer du col de l'utéruspublished 2022BMC public healthPubMeddocument of 6 observations
75.9 %Before the intervention, 75.9% of participants were afraid of being diagnosed with cervical cancer.
Nigeriacancer du col de l'utéruspublished 2023BMC women's healthPubMeddocument of 7 observations
50 %Nearly half of women diagnosed with cervical cancer in Sub-Saharan Africa die within 3 years.
Nigeriacancer du col de l'utéruspublished 2026Rural and remote healthPubMeddocument of 21 observations
26.2 per_100000Cervical cancer is the second most common cancer amongst women in Nigeria, with an incidence rate of 26.2 per 100,000.
Nigeriacancer du col de l'utéruspublished 2025The Pan African medical journalPubMeddocument of 10 observations
3.2 %Only 3.2% of women in urban slums of Lagos, Nigeria had heard of cervical cancer.
Nigeriacancer du col de l'utéruspublished 2022West African journal of medicinePubMeddocument of 13 observations
73.2 %73.2% of women in Taraba, North-East Nigeria had appropriate knowledge about the nature of cervical cancer.
Nigeriacancer du col de l'utéruspublished 2019Asian Pacific journal of cancer prevention : APJCPPubMeddocument of 6 observations
55.31 %55.31% of the respondents identified the Pap Smear test as the most commonly known method of cervical screening.
Nigeriacancer du col de l'utéruspublished 2024African health sciencesPubMeddocument of 5 observations
65.3 %The level of knowledge of different aspects of cervical cancer was 65.3% among women of a Catholic Parish in Nsukka Local Government Area of Enugu State, Nigeria.
Nigeriacancer du col de l'utéruspublished 2021The Pan African medical journalPubMeddocument of 8 observations
76.8 %The level of awareness of cervical cancer among the respondents was 76.8%.
Nigeriacancer du col de l'utérusobserved 2017published 2022The Pan African medical journalPubMeddocument of 7 observations
62.8 %62.8% (27/43) of art entries addressed 'perceptions' of art as a means of mental and emotional expression related to cervical cancer prevention.
Nigeriacancer du col de l'utéruspublished 2026JMIR formative researchPubMeddocument of 7 observations
76.5 %76.5% of women in Taraba, North-East Nigeria had appropriate knowledge about the signs and symptoms of cervical cancer.
Nigeriacancer du col de l'utéruspublished 2019Asian Pacific journal of cancer prevention : APJCPPubMeddocument of 6 observations
3 %VIA positivity was 3% among the general population.
Nigeriacancer du col de l'utérusobserved 2021published 2023BMC public healthPubMeddocument of 12 observations
Les projets de démonstration de l’efficacité et de la performance de l’IVA pour le dépistage du cancer du col utérin montrent des résultats concluants à Madagascar, au Malawi, au Nigéria, en Ouganda, en Tanzanie et en Zambie en 2009.
Madagascar · Malawi · Nigeria · Ouganda · Tanzaniecancer du col de l'utérusobserved 2009HAL · Unilimdocument of 81 observations
29 %Among female undergraduates in a tertiary institution in south eastern Nigeria, cervical cancer screening uptake was higher among married females (29%) compared to single females (5.2%).
Nigeriacancer du col de l'utéruspublished 2021Journal of preventive medicine and hygienePubMeddocument of 11 observations
1.5 %1.5% of eligible participants reported having had cervical cancer screening.
Nigeriacancer du col de l'utérusobserved April 2018published 2021BMJ openPubMeddocument of 10 observations
88.5 %The diffuse pattern of PD-L1 staining accounted for 88.5% of positive cases.
Nigeriacancer du col de l'utérusobserved 2012–2016published 2022PloS onePubMeddocument of 6 observations
77.48 GyThe mean dose to D90 of the HR-CTV was 77.48 ± 6.95 Gy in Group A patients.
Nigeriacancer du col de l'utéruspublished 2025BrachytherapyPubMeddocument of 8 observations
Every row leads to its source document. The figure shown counts the VALIDATED observations it carries, never the extracted ones: the two differ on most documents. The exact source excerpt is not published, due to copyright constraints.